Literature DB >> 20177735

Avascular necrosis of the femoral head: a rare class-effect of anti-VEGF agents.

Olivier Mir1, Romain Coriat, Thomas Gregory, Stanislas Ropert, Bertrand Billemont, François Goldwasser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20177735     DOI： 10.1007/s10637-010-9406-6

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  6 in total

Review 1.  Osteonecrosis of the femoral head: etiology, imaging and treatment.

Authors:  Konstantinos N Malizos; Apostolos H Karantanas; Sokratis E Varitimidis; Zoe H Dailiana; Konstantinos Bargiotas; Thomas Maris
Journal:  Eur J Radiol       Date:  2007-06-06       Impact factor: 3.528

2.  Sorafenib-induced bilateral osteonecrosis of femoral heads.

Authors:  Marielle Guillet; Thomas Walter; Jean-Yves Scoazec; Thierry Vial; Catherine Lombard-Bohas; Jérôme Dumortier
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

3.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

4.  Differential expression of vascular endothelial growth factor in glucocorticoid-related osteonecrosis of the femoral head.

Authors:  Deike Varoga; Wolf Drescher; Melanie Pufe; Godo Groth; Thomas Pufe
Journal:  Clin Orthop Relat Res       Date:  2009-12       Impact factor: 4.176

Review 5.  Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: a systematic review.

Authors:  Katharine Shim; Mary J MacKenzie; Eric Winquist
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

6.  Vascular endothelial growth factor in rabbits during development of corticosteroid-induced osteonecrosis: a controlled experiment.

Authors:  Tamon Kabata; Tadami Matsumoto; Shinichi Yagishita; Tomohiko Wakayama; Shoichi Iseki; Katsuro Tomita
Journal:  J Rheumatol       Date:  2008-11-01       Impact factor: 4.666
  6 in total
  5 in total

1.  Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis.

Authors:  Tessa Tabouret; Thomas Gregory; Marion Dhooge; Catherine Brezault; Olivier Mir; Johann Dréanic; Stanislas Chaussade; Romain Coriat
Journal:  Invest New Drugs       Date:  2015-08-28       Impact factor: 3.850

2.  Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.

Authors:  Jason Fangusaro; Sridharan Gururangan; Regina I Jakacki; Sue C Kaste; Stewart Goldman; Ian F Pollack; James M Boyett; Larry E Kun
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

Review 3.  Osteocyte apoptosis.

Authors:  Robert L Jilka; Brendon Noble; Robert S Weinstein
Journal:  Bone       Date:  2012-12-11       Impact factor: 4.398

4.  Exploring adverse drug events at the class level.

Authors:  Rainer Winnenburg; Alfred Sorbello; Olivier Bodenreider
Journal:  J Biomed Semantics       Date:  2015-05-01

5.  Bevacizumab-associated osteonecrosis of the femur and tibia.

Authors:  Leandro J C Oliveira; Felipe S N A Canedo; Karina P Sacardo; João V M Alessi; Felipe G Barbosa; Andrea K Shimada; Artur Katz
Journal:  Oxf Med Case Reports       Date:  2019-05-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.